Press coverage about Integra Lifesciences (NASDAQ:IART) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Integra Lifesciences earned a media sentiment score of 0.02 on Accern’s scale. Accern also gave media stories about the life sciences company an impact score of 46.8817819333759 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the news articles that may have effected Accern’s analysis:
- Contrasting Integra Lifesciences (IART) & T2 Biosystems (TTOO) (americanbankingnews.com)
- Integra Lifesciences Holdings Corp Forecasted to Post FY2017 Earnings of $1.84 Per Share (IART) (americanbankingnews.com)
- Integra Lifesciences’ (IART) “Hold” Rating Reiterated at Barclays (americanbankingnews.com)
- Integra Lifesciences Holdings Corp (IART) Receives Average Rating of “Hold” from Analysts (americanbankingnews.com)
- Integra LifeSciences Sees Q4 Revenue Above View (markets.businessinsider.com)
IART has been the topic of several recent analyst reports. Oppenheimer reissued a “buy” rating and issued a $60.00 target price on shares of Integra Lifesciences in a report on Monday, September 18th. Zacks Investment Research raised shares of Integra Lifesciences from a “hold” rating to a “buy” rating and set a $57.00 price target on the stock in a report on Tuesday, October 3rd. Jefferies Group reiterated a “buy” rating and set a $58.00 target price on shares of Integra Lifesciences in a research report on Thursday, October 12th. JPMorgan Chase & Co. downgraded shares of Integra Lifesciences from an “overweight” rating to a “neutral” rating and set a $44.00 price target on the stock. in a research report on Friday, October 27th. Finally, TheStreet downgraded shares of Integra Lifesciences from a “b” rating to a “c+” rating in a research report on Thursday, October 26th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and three have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $52.70.
Integra Lifesciences (NASDAQ:IART) last issued its earnings results on Thursday, October 26th. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.47 by ($0.02). Integra Lifesciences had a return on equity of 16.35% and a net margin of 4.52%. The firm had revenue of $278.83 million during the quarter, compared to the consensus estimate of $286.00 million. During the same quarter in the prior year, the business posted $0.93 EPS. The firm’s revenue for the quarter was up 11.4% on a year-over-year basis. equities analysts anticipate that Integra Lifesciences will post 1.85 earnings per share for the current fiscal year.
In other Integra Lifesciences news, VP Richard D. Gorelick sold 1,500 shares of the business’s stock in a transaction dated Tuesday, November 14th. The stock was sold at an average price of $47.19, for a total transaction of $70,785.00. Following the completion of the sale, the vice president now directly owns 21,665 shares in the company, valued at approximately $1,022,371.35. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Barbara B. Hill acquired 10,768 shares of the stock in a transaction dated Tuesday, October 31st. The shares were bought at an average cost of $46.66 per share, for a total transaction of $502,434.88. Following the completion of the transaction, the director now owns 55,540 shares in the company, valued at $2,591,496.40. The disclosure for this purchase can be found here. Company insiders own 21.50% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Integra Lifesciences (NASDAQ:IART) Earns Daily Media Impact Rating of 0.02” was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://stocknewstimes.com/2018/01/11/integra-lifesciences-iart-earning-somewhat-favorable-news-coverage-analysis-finds.html.
Integra Lifesciences Company Profile
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.